Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results
Cardiovascular disease is the leading cause of mortality in women and mortality rate has remained greater for women (than men); but till recently risk of CAD and MI was not considered real specially in younger women. However, over the last decade, there have been marked reductions
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
